TherapeuticsMD, Inc. (NASDAQ:TXMD – Get Free Report) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 21,100 shares, a drop of 29.9% from the November 15th total of 30,100 shares. Based on an average daily volume of 16,300 shares, the short-interest ratio is presently 1.3 days. Currently, 0.2% of the shares of the stock are sold short.
TherapeuticsMD Stock Down 2.4 %
TXMD stock traded down $0.03 during mid-day trading on Friday, reaching $1.22. The company’s stock had a trading volume of 8,889 shares, compared to its average volume of 17,653. The company’s 50 day moving average is $1.46 and its two-hundred day moving average is $1.68. TherapeuticsMD has a fifty-two week low of $1.15 and a fifty-two week high of $2.75.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of TherapeuticsMD in a research note on Monday. They set a “hold” rating for the company.
Institutional Investors Weigh In On TherapeuticsMD
A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 18.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. Institutional investors own 30.74% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- How to Invest in Blue Chip Stocks
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Using the MarketBeat Dividend Tax Calculator
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How is Compound Interest Calculated?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.